ArticleClinical proteomics2017
A multiplex platform for the identification of ovarian cancer biomarkers.
Article in Clinical proteomics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 98 citations in OpenAlex.
- Review
- Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication.Journal of clinical laboratory analysis · 2026Article
- Repurposing the liquid-based Pap test for the detection of ovarian cancer protein biomarkers.Clinical proteomics · 2026Article
- Assessing Random Forest self-reproducibility for optimal short biomarker signature discovery.Briefings in bioinformatics · 2025Article
- Significance of Midkine Signaling in Women's Cancers: Novel Biomarker and Therapeutic Target.International journal of molecular sciences · 2025Review
- Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Evaluation of Serum Proteome Sample Preparation Methods to Support Clinical Proteomics Applications.Journal of the American Society for Mass Spectrometry · 2024Article
- Clinical Significance of TNFSF14/LIGHT and CD160 in Gastric Cancer and Peptic Ulcer Dyspepsia.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Quantification of putative ovarian cancer serum protein biomarkers using a multiplexed targeted mass spectrometry assay.Clinical proteomics · 2024Article
- Recent Advances in Surface Plasmon Resonance (SPR) Technology for Detecting Ovarian Cancer Biomarkers.Cancers · 2023Review
- Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics.Diagnostics (Basel, Switzerland) · 2023Review
- Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer.Cancers · 2022Article
- Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.Molecules (Basel, Switzerland) · 2021Review
- Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics.Clinical proteomics · 2021Article
- Comparison of two multiplexed technologies for profiling >1,000 serum proteins that may associate with tumor burden.F1000Research · 2021Article
- A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors.Neuroendocrinology · 2021Observational
- Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.BMC cancer · 2020Article
- Does the Use of the "ProseekJournal of clinical medicine · 2020Article
- Non-invasive Technology Advances in Cancer-A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers.Frontiers in digital health · 2020Review
- Investigating a novel multiplex proteomics technology for detection of changes in serum protein concentrations that may correlate to tumor burden.F1000Research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCurrently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients.
methodsWe used a multiplex approach to identify protein biomarkers for detecting early stage ovarian cancer. This new technology (Proseek
resultsPrinciple component analysis and unsupervised hierarchical clustering separated patients into cancer versus non-cancer subgroups. Data from the Proseek
conclusionsThese data demonstrate that the Proseek
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.